Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma

BACKGROUND: Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorable response to immunotherapy. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Landon C, Zhu, Jason, Desai, Kunal, Kinsey, Emily, Kao, Chester, Lee, Yong Hee, Pabla, Sarabjot, Labriola, Matthew K, Tran, Jennifer, Dragnev, Konstantin H, Tafe, Laura J, Dayyani, Farshid, Gupta, Rajan T, McCall, Shannon, George, Daniel J, Glenn, Sean T, Nesline, Mary K, George, Saby, Zibelman, Matthew, Morrison, Carl, Ornstein, Moshe C, Zhang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577926/
https://www.ncbi.nlm.nih.gov/pubmed/36252996
http://dx.doi.org/10.1136/jitc-2022-005249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577926/
https://www.ncbi.nlm.nih.gov/pubmed/36252996
http://dx.doi.org/10.1136/jitc-2022-005249

Ejemplares similares